Does REGORAFENIB Cause Tumour marker increased? 69 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 69 reports of Tumour marker increased have been filed in association with REGORAFENIB (Stivarga). This represents 0.7% of all adverse event reports for REGORAFENIB.
69
Reports of Tumour marker increased with REGORAFENIB
0.7%
of all REGORAFENIB reports
13
Deaths
18
Hospitalizations
How Dangerous Is Tumour marker increased From REGORAFENIB?
Of the 69 reports, 13 (18.8%) resulted in death, 18 (26.1%) required hospitalization, and 1 (1.4%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 69 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which REGORAFENIB Alternatives Have Lower Tumour marker increased Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR